AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing

Company Performance - AbbVie (ABBV) closed at $190.58, marking a +2.25% move from the prior day, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, AbbVie shares appreciated by 0.49%, while the Medical sector experienced a loss of 3.4% [1] Upcoming Earnings - AbbVie is expected to release its earnings report on July 31, 2025, with analysts forecasting earnings of $3.02 per share, indicating a year-over-year growth of 13.96% [2] - The consensus estimate anticipates revenue of $15.04 billion, reflecting a 3.97% increase from the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $12.07 per share and revenue of $60.12 billion, representing shifts of +19.27% and +6.72% respectively from the previous year [3] - Recent changes in analyst estimates suggest a favorable outlook on AbbVie's business health and profitability [3] Valuation Metrics - AbbVie is currently trading at a Forward P/E ratio of 15.44, which is a premium compared to the industry average of 14.02 [6] - The company has a PEG ratio of 1.23, aligning with the average PEG ratio of the Large Cap Pharmaceuticals industry [7] Industry Ranking - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]